Radium-223 mechanism of action: implications for use in treatment combinations
The targeted alpha therapy radium-223 (223Ra) can prolong survival in men with castration-
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
Radium-223 mechanism of action: implications for use in treatment combinations
MJ Morris, E Corey, TA Guise, JL Gulley… - Nature Reviews …, 2019 - pure.johnshopkins.edu
The targeted alpha therapy radium-223 (223 Ra) can prolong survival in men with castration-
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
[HTML][HTML] Radium-223 mechanism of action: implications for use in treatment combinations
MJ Morris, E Corey, TA Guise, JL Gulley… - Nature reviews …, 2019 - ncbi.nlm.nih.gov
The targeted alpha therapy radium-223 (223 Ra) can prolong survival in men with castration-
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
Radium-223 mechanism of action: implications for use in treatment combinations
MJ Morris, E Corey, TA Guise… - Nature reviews …, 2019 - pubmed.ncbi.nlm.nih.gov
The targeted alpha therapy radium-223 (223 Ra) can prolong survival in men with castration-
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
Radium-223 mechanism of action: implications for use in treatment combinations
MJ Morris, E Corey, TA Guise, JL Gulley, W Kevin Kelly… - Nature, 2019 - hero.epa.gov
The targeted alpha therapy radium-223 (223Ra) can prolong survival in men with castration-
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
Radium-223 mechanism of action: implications for use in treatment combinations.
MJ Morris, E Corey, TA Guise, JL Gulley… - Nature reviews …, 2019 - europepmc.org
The targeted alpha therapy radium-223 (223 Ra) can prolong survival in men with castration-
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
[引用][C] Radium-223 mechanism of action: implications for use in treatment combinations
MJ Morris, E Corey, TA Guise, JL Gulley… - Nature Reviews …, 2019 - cir.nii.ac.jp
Radium-223 mechanism of action: implications for use in treatment combinations | CiNii
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 …
Radium-223 mechanism of action: implications for use in treatment combinations
MJ Morris, E Corey, TA Guise… - Nature …, 2019 - mdanderson.elsevierpure.com
The targeted alpha therapy radium-223 (223 Ra) can prolong survival in men with castration-
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
Radium-223 mechanism of action: implications for use in treatment combinations
MJ Morris, E Corey, TA Guise, JL Gulley… - Nature Reviews …, 2019 - search.proquest.com
The targeted alpha therapy radium-223 (223 Ra) can prolong survival in men with castration-
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …
resistant prostate cancer (CRPC) who have symptomatic bone metastases and no known …